Skip to content

Summary

A study to evaluate nivolumab + chemotherapy or nivolumab/ BMS-986205 + chemotherapy followed by continued Immuno-Oncology therapy after radical cystectomy (RC) compared with neoadjuvant standard of care (SOC) chemotherapy alone in patients with muscle-invasive bladder cancer (MIBC)

Acronym:

CA017-078

ACTRN/NCT /ethics:

NCT03661320

Scientific title:

A phase 3, randomised study of neoadjuvant chemotherapy alone versus neoadjuvant chemotherapy plus nivolumab or nivolumab and BMS-986205, followed by continued post-surgery therapy with nivolumab or nivolumab and BMS-986205 in participants with muscle-invasive bladder cancer

Sponsor / Cooperative group

Bristol-Myers Squibb

Trial & Patient Characteristics

Cancer TypeBladder
Trial TypeTreatment
PhasePhase III
Age Range18+ years
SexBoth
Tumour StreamBladder
Cancer StageAll stages
Anticipated Start Date2018-10-12
Anticipated End Date2026-12-30

Participating Hospitals

HospitalCalvary North Adelaide Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruitment on Hold